Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Icotinib||BPI-2009|BPI-2009H|Conmana||EGFR Inhibitor 1st gen 3||Icotinib (BPI-2009) is a selective EGFR inhibitor that inhibits both wild-type and mutant forms of EGFR, which may result in decreased tumor cell proliferation (PMID: 22112293).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|ERBB2 V659E||lung non-small cell carcinoma||predicted - sensitive||Icotinib||Case Reports/Case Series||Actionable||In a clinical case study, a patient with non-small cell lung cancer harboring ERBB2 (HER2) V659E achieved six months of progression-free survival with Icotinib treatment, prior to disease progression (PMID: 32478891).||32478891|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|
|NCT02033148||Phase I||Icotinib||Icotinib Hydrochloride in Treating Patients With Advanced Cancers||Withdrawn|